Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism.
The E46K is a point mutation in alpha-synuclein (alpha-syn) that causes familial Parkinsonism with Lewy body dementia. We have now generated a cell model of Parkinsonism/Parkinson's disease (PD) and demonstrated cell toxicity after expression of E46K in the differentiated PC12 cells. E46K alpha-syn inhibited proteasome activity and induced mitochondrial depolarization in the cell model. Baicalein has been reported to inhibit fibrillation of wild type alpha-syn in vitro, and to protect neurons against several chemical-induced models of PD. We now report that baicalein significantly attenuated E46K-induced mitochondrial depolarization and proteasome inhibition, and protected cells against E46K-induced toxicity in a cell model of PD. Baicalein also reduced E46K fibrilization in vitro, with a concentration-dependent decrease in beta sheet conformation, though it increased some oligomeric species, and decreased formation of E46K alpha-syn-induced aggregates and rescued toxicity in N2A cells. Taken together, these data indicate that mitochondrial dysfunction, proteasome inhibition and specific aspects of abnormal E46K aggregation accompany E46K alpha-syn-induced cell toxicity, and baicalein can protect as well as altering aggregation properties. Baicalein has potential as a tool to understand the relation between different aggregation species and toxicity, and might be a candidate compound for further validation by using in vivo alpha-syn genetic PD models.
Jiang
Mali
M
Division of Neurobiology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Porat-Shliom
Yair
Y
Pei
Zhong
Z
Cheng
Yong
Y
Xiang
Lan
L
Sommers
Katherine
K
Li
Qing
Q
Gillardon
Frank
F
Hengerer
Bastian
B
Berlinicke
Cynthia
C
Smith
Wanli W
WW
Zack
Donald J
DJ
Poirier
Michelle A
MA
Ross
Christopher A
CA
Duan
Wenzhen
W
D000818:Animals; D016923:Cell Death; D002454:Cell Differentiation; D044950:Flavanones / Q000494:pharmacology*; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D009154:Mutation; D009474:Neurons / Q000378:metabolism / Q000648:ultrastructure; D016716:PC12 Cells; D020734:Parkinsonian Disorders / Q000235:genetics / Q000378:metabolism*; D061988:Proteasome Inhibitors; D051381:Rats; D051844:alpha-Synuclein / Q000096:biosynthesis / Q000235:genetics*
D044950:Flavanones; D061988:Proteasome Inhibitors; D051844:alpha-Synuclein; C006680:baicalein
Eur J Pharmacol. 2004 Dec 3;506(1):55-61
15588624
Biochem Biophys Res Commun. 2008 Jan 25;365(4):833-9
18039462
FEBS Lett. 2004 Oct 22;576(3):363-8
15498564
Hum Mol Genet. 2005 Dec 15;14(24):3801-11
16239241
Antioxid Redox Signal. 2009 Sep;11(9):2135-49
19422283
Neurobiol Aging. 2010 Jun;31(6):953-68
18715677
FEBS Lett. 1998 Nov 27;440(1-2):67-70
9862427
Am J Pathol. 1998 Apr;152(4):879-84
9546347
Science. 1997 Jun 27;276(5321):2045-7
9197268
Ann N Y Acad Sci. 2003 Jun;991:1-14
12846969
Neurobiol Dis. 2005 Nov;20(2):500-8
15908226
Science. 2003 Oct 31;302(5646):841
14593171
Biochem J. 2009 Mar 1;418(2):311-23
19007333
Pharmacol Biochem Behav. 2009 Jun;92(4):642-8
19327378
Neurobiol Dis. 2006 May;22(2):404-20
16439141
J Biol Chem. 2005 Mar 4;280(9):7800-7
15632170
Neuroscience. 2007 Dec 12;150(3):585-91
17942241
Anticancer Res. 2000 Sep-Oct;20(5A):2861-5
11062694
Brain Nerve. 2007 Aug;59(8):851-64
17713121
Hum Mol Genet. 2001 Apr 15;10(9):919-26
11309365
Nat Genet. 1998 Feb;18(2):106-8
9462735
Trends Neurosci. 2005 Aug;28(8):416-21
15955578
J Biol Chem. 2009 Apr 10;284(15):10211-22
19203998
Arch Neurol. 2008 Dec;65(12):1577-81
19064744
Am J Pathol. 2000 Aug;157(2):401-10
10934145
Biochemistry. 2007 Jun 19;46(24):7107-18
17530780
Curr Pharm Des. 2008;14(30):3247-66
19075704
Mol Med. 2008 Jul-Aug;14(7-8):451-64
18368143
Nature. 1997 Aug 28;388(6645):839-40
9278044
Exp Neurol. 2006 Feb;197(2):515-20
16325180
Biochim Biophys Acta. 2009 Jul;1792(7):616-24
18955133
Eur J Cell Biol. 2005 Nov;84(11):897-905
16323286
Toxicology. 2006 Sep 21;226(2-3):238-45
16887252
Neuron. 2003 Oct 30;40(3):453-6
14642269
Ann Neurol. 2004 Feb;55(2):164-73
14755719
Biochemistry. 2007 Nov 6;46(44):12522-9
17927212
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76
18344392
J Neurosci. 2001 Dec 15;21(24):9549-60
11739566
J Pharmacol Sci. 2005 Jun;98(2):185-9
15942123
J Biol Chem. 2004 Jun 25;279(26):26846-57
15096521
Acc Chem Res. 2006 Sep;39(9):628-34
16981679
Arch Biochem Biophys. 2006 Sep 1;453(1):75-86
16530158
J Biomol Struct Dyn. 2003 Oct;21(2):211-34
12956606
Int J Biochem Cell Biol. 2005 May;37(5):942-6
15743669
J Biol Chem. 2008 Apr 18;283(16):10992-1003
18258594
Curr Protein Pept Sci. 2008 Oct;9(5):507-40
18855701
Free Radic Biol Med. 2000 Nov 15;29(10):1037-42
11084292
Biochemistry. 2009 Sep 1;48(34):8206-24
19634918
Nat Med. 2004 Jul;10 Suppl:S10-7
15272267
Eur J Neurol. 2003 May;10(3):281-6
12752402
Bull Acad Natl Med. 2006 Feb;190(2):485-96; discussion 497-8
17001874
Trends Neurosci. 1998 Jun;21(6):249-54
9641537
J Mol Biol. 2002 Oct 4;322(5):1089-102
12367530
J Mol Biol. 2008 Oct 31;383(1):214-23
18775438
Neurosci Lett. 2008 Aug 15;441(1):16-20
18586394
Med Sci (Paris). 2003 May;19(5):613-9
12836396
Nature. 2002 Jul 18;418(6895):291
12124613
J Neurosci Res. 1999 Oct 1;58(1):120-9
10491577
J Mol Neurosci. 2002 Jun;18(3):229-38
12059041